Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study.

ABSTRACT:

Background

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) exhibit promising lipid-lowering activity, but evidence regarding their effectiveness in real-world diabetic populations is limited.

Methods

Based on TriNetX database, individuals T2D and dyslipidemia who were newly prescribed either a PCSK9 inhibitor or a statin between January 1, 2015, and April 30, 2025, were identified. After propensity score matching, 20,489 patients were classified into each treatment group. Primary endpoints were defined as a composite of all-cause mortality, major adverse cardiovascular events (MACE), and major adverse kidney events (MAKE) during the 5-year follow-up.

Results

PCSK9i use was associated with a reduced incidence of the primary outcome (hazard ratio [HR]

SUBMITTER: Wu JY 

PROVIDER: S-EPMC12672303 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature